Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.58 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10367869 | 0.91 | CCR5 (0.60) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL17197395 | 0.88 | CCR5 (0.62) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL8406943 | 0.88 | HTR1A (0.65) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL3724781 | 0.88 | CCR5 (0.66) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL27402118 | 0.86 | CCR5 (0.60) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL16294248 | 0.85 | USP28 (0.69) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL16293879 | 0.85 | CCR5 (0.59) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL6260325 | 0.85 | CCR5 (0.59) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL27403102 | 0.84 | CCR5 (0.76) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL7585417 | 0.84 | CCR5 (0.58) | CCR5ALDH1A1RAB9AUSP28USP25 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312906-B2 | Polymerizable monomer, liquid crystal composition using polymerizable monomer, and liquid crystal display device | DIC CORPORATION (JP) | 2022-04-26 | — | — | US | disclosed |
| US-11312906-B2 | Polymerizable monomer, liquid crystal composition using polymerizable monomer, and liquid crystal display device | DIC CORPORATION (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200224098-A1 | POLYMERIZABLE MONOMER, LIQUID CRYSTAL COMPOSITION USING POLYMERIZABLE MONOMER, AND LIQUID CRYSTAL DISPLAY DEVICE | DIC CORPORATION (JP) | 2020-07-16 | — | — | US | disclosed |
| US-20200224098-A1 | POLYMERIZABLE MONOMER, LIQUID CRYSTAL COMPOSITION USING POLYMERIZABLE MONOMER, AND LIQUID CRYSTAL DISPLAY DEVICE | DIC CORPORATION (JP) | 2020-07-16 | — | — | US | disclosed |
| CN-110651022-A | Polymerizable monomer, liquid crystal composition using same, and liquid crystal display element | DIC株式会社 | 2020-01-03 | — | — | CN | disclosed |
| EP-1194147-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-6465497-B2 | SUBSTITUTED 5-ARYL-2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES; AGONISTS OF PPAR (PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR); USEFUL TREATING DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND OBESITY | MERCK & CO., INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1194147-A4 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6380191-B1 | FOR TREATMENT, CONTROL OR PREVENTION OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA (INCLUDING HYPERCHOLESTEROLEMIA AND HYPERTRIGLYCERIDEMIA), ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO. INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1194147-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2000078313-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | PPARD, PPARA, PPARG | CCR5 726/4885ALDH1A1 679/4885RAB9A 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.